Cure8 research brief
The paper reports blood immune signatures linked to vedolizumab response in ulcerative colitis, which could help develop biomarkers to predict who benefits from this anti‑integrin therapy.
Clinicians treating UC with biologics; researchers studying IBD immunobiology and biomarkers; patients on or considering vedolizumab
The researchers used mass cytometry (a 38-marker panel) on peripheral blood mononuclear cells from healthy controls and UC patients stratified by vedolizumab exposure and clinical response. Responders had more α4β7+ effector memory CD4+ T cells and fewer class-switched plasmablasts/activated B cells compared with vedolizumab‑naive UC patients.
Non-responders were enriched for an α4β7+ atypical-like IgA+ memory B‑cell subset. The authors conclude these circulating signatures are associated with response status but note prospective studies are needed to test whether signatures predict response before treatment or reflect changes after therapy.
Findings are from a mass‑cytometry cohort and are associative. Authors state prospective studies are needed to test predictive versus pharmacodynamic roles of the signatures.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
If validated, metabolite patterns could help predict which children will reach remission on vedolizumab, potentially guiding treatment choices and avoiding ineffective therapy.
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
